论文部分内容阅读
目的探讨前列地尔(PGE1)治疗急性肾损伤(Acute Kidney Injury,AKI)的临床疗效。方法收集海南省人民医院肾病风湿科自2010年1月～2012年1月住院治疗的急性肾损伤患者56例,随机分为治疗组(28例)和对照组(28例)。两组常规用药相同,治疗组加用PGE1静脉滴注,每天1次,连续2周。比较两组患者治疗前后尿NAG酶、尿渗透压、血肌酐、尿素氮、尿β2微球蛋白以及肾衰指数、肾小球滤过率及进入透析人数的变化。结果治疗组治疗后,尿NAG酶、血肌酐、尿素氮、尿β2微球蛋白以及肾衰指数明显低于对照组,尿渗透压、肾小球滤过率明显高于对照组(P﹤0.05)。治疗组进入透析的人数(6人)低于对照组(13人)(χ2=3.9,P﹤0.05)。结论 PGE1可促进AKI缓解,增强疗效。
Objective To investigate the clinical efficacy of prostaglandin (PGE1) in the treatment of acute kidney injury (AKI). Methods Fifty-six patients with acute kidney injury who were hospitalized in Department of Nephrology Rheumatism of Hainan Provincial People’s Hospital from January 2010 to January 2012 were randomly divided into treatment group (n = 28) and control group (n = 28). The same two groups of conventional medication, the treatment group plus PGE1 intravenous infusion, once daily for 2 weeks. Urinary NAG, urinary osmotic pressure, serum creatinine, urea nitrogen, urinary β2 microglobulin and renal failure index, glomerular filtration rate and the number of dialysis patients were compared before and after treatment. Results After treatment, urinary NAG enzyme, serum creatinine, urea nitrogen, urinary β2 microglobulin and renal failure index were significantly lower in the treatment group than in the control group. Urinary osmotic pressure and glomerular filtration rate were significantly higher than those in the control group (P <0.05 ). The number of dialysis patients in the treatment group (6) was lower than that in the control group (13) (χ2 = 3.9, P <0.05). Conclusions PGE1 can promote the remission of AKI and enhance the curative effect.